首页> 外文OA文献 >Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival
【2h】

Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival

机译:同时诊断骨髓增生异常综合征患者中具有预后价值的14个基因的表达的分析:外周血中WT1检测对存活率产生不利影响

摘要

Several studies have evaluated the prognostic value of the individual expression of certain genes in patients with myelodysplastic syndromes (MDS). However, none of them includes their simultaneous analysis by quantitative polymerase chain reaction (PCR). We evaluated relative expression levels of 14 molecular markers in 193 peripheral blood samples from untreated MDS patients using real-time PCR. Detectable WT1 expression levels, low TET2, and low IER3 gene expression were the only markers showing in univariate analysis a poor prognostic value for all treatment-free (TFS), progression-free (PFS), and overall survival (OS). In multivariate analysis, molecular parameters associated with a shorter TFS were: WT1 detection (p=0.014), low TET2 (p=0.002), and low IER3 expression (p=0.025). WT1 detection (p=0.006) and low TET2 (p=0.006) expression were associated with a shorter PFS when multivariate analysis was carried out by including only molecular markers. Molecular values with an independent value in OS were: WT1 detection (p=0.003), high EVI1 expression (p=0.001), and undetectatable p15-CDKN2B (p=0.037). WT1 expressers were associated with adverse clinical-biological features, high IPSS and WPSS scoring, and unfavorable molecular expression profile. In summary, detectable WT1 expression levels, and low TET2 and low IER3 expression in peripheral blood showed a strong association with adverse prognosis in MDS patients at diagnosis. However, WT1 was the only molecular marker displaying an independent prognostic value in both OS and TFS.
机译:几项研究评估了某些基因个体表达在骨髓增生异常综合症(MDS)患者中的预后价值。但是,它们都不包括通过定量聚合酶链反应(PCR)进行的同时分析。我们使用实时PCR评估了来自未经治疗的MDS患者的193份外周血样品中14种分子标记的相对表达水平。可检测的WT1表达水平,TET2低表达和IER3基因低表达是单变量分析中所有无治疗(TFS),无进展(PFS)和总体生存(OS)的不良预后价值的唯一标志。在多变量分析中,与较短TFS相关的分子参数为:WT1检测(p = 0.014),TET2低(p = 0.002)和IER3低表达(p = 0.025)。当仅通过分子标记进行多变量分析时,WT1检测(p = 0.006)和低TET2(p = 0.006)表达与较短的PFS相关。在OS中具有独立值的分子值为:WT1检测(p = 0.003),EVI1高表达(p = 0.001)和不可检测的p15-CDKN2B(p = 0.037)。 WT1表达与不良的临床生物学特征,较高的IPSS和WPSS评分以及不良的分子表达谱有关。总之,在诊断时,MDS患者外周血中可检测到的WT1表达水平,低TET2和低IER3表达与不良预后密切相关。然而,WT1是唯一在OS和TFS中均显示独立预后价值的分子标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号